Clinical stage biopharmaceutical company Paradigm Biopharmaceuticals (ASX: PAR) has been given the green light to go ahead with a Phase…
The commercialisation of osteoarthritis treatment ZILOSUL® has hit a hiccup in the United States with the US Food and Drug…
Professional athletes may soon have a new treatment for knee osteoarthritis after Paradigm Biopharmaceuticals (ASX: PAR) received glowing endorsements from…
Osteoarthritis sufferers could soon receive effective pain relief and reduced onset from the degenerative disease after Paradigm Biopharmaceuticals (ASX: PAR)…